Home › Compare › JWCTF vs BTI

JWCTF vs BTI: Dividend Comparison 2026

JWCTF yields 651.47% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JWCTF wins by $503577.86M in total portfolio value
10 years
JWCTF
JWCTF
● Live price
651.47%
Share price
$0.31
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$503577.90M
Annual income
$386,785,137,245.59
Full JWCTF calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — JWCTF vs BTI

📍 JWCTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJWCTFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JWCTF + BTI cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
JWCTF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JWCTF
Annual income on $10K today (after 15% tax)
$55,374.59/yr
After 10yr DRIP, annual income (after tax)
$328,767,366,658.75/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, JWCTF beats the other by $328,767,364,290.11/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JWCTF + BTI for your $10,000?

JWCTF: 50%BTI: 50%
100% BTI50/50100% JWCTF
Portfolio after 10yr
$251788.97M
Annual income
$193,392,570,016.11/yr
Blended yield
76.81%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

JWCTF
No analyst data
Altman Z
-9.3
Piotroski
3/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JWCTF buys
0
BTI buys
0
No recent congressional trades found for JWCTF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJWCTFBTI
Forward yield651.47% ✓5.38%
Annual dividend / share$2.00$3.15 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3% ✓
Portfolio after 10y$503577.90M ✓$37.7K
Annual income after 10y$386,785,137,245.59 ✓$2,786.64
Total dividends collected$493990.56M ✓$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: JWCTF vs BTI ($10,000, DRIP)

YearJWCTF PortfolioJWCTF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$75,847$65,146.58$11,299$598.92+$64.5K → JWCTF
2$542,945$461,789.28$12,794$703.91+$530.2K → JWCTF
3$3,670,393$3,089,441.65$14,518$829.07+$3.66M → JWCTF
4$23,446,108$19,518,787.95$16,513$978.64+$23.43M → JWCTF
5$141,614,527$116,527,191.03$18,827$1,157.84+$141.60M → JWCTF
6$809,307,352$657,779,808.21$21,518$1,373.12+$809.29M → JWCTF
7$4,379,155,354$3,513,196,486.95$24,657$1,632.46+$4379.13M → JWCTF
8$22,451,936,399$17,766,240,170.59$28,329$1,945.74+$22451.91M → JWCTF
9$109,152,115,265$85,128,543,318.27$32,637$2,325.33+$109152.08M → JWCTF
10$503,577,900,579$386,785,137,245.59$37,708$2,786.64+$503577.86M → JWCTF

JWCTF vs BTI: Complete Analysis 2026

JWCTF — Stock

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.

Full JWCTF Calculator →

BTI — Consumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this JWCTF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JWCTF vs SCHDJWCTF vs JEPIJWCTF vs OJWCTF vs KOJWCTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.